Before the two STAP cell papers were published in Nature in January of 2014, much of the same data was reportedly submitted as single papers to other high-profile journals including Science. In these cases, the proto-STAP papers as we might call them were rejected. But why? Until now we largely could only speculate. However, the reviews […]
Full Reviews of Rejected STAP Paper Point to Early Signs of Big Trouble Read More »
Here is the second installment in my “elephant in the lab” series, which addresses controversial or even taboo topics in laboratories and the sciences. The first segment was on taboo topics in the iPS cell field. People loved the honesty of that post. Today I am talking about how sometimes scientists kill each other’s papers
Dirty dozen easy steps to killing a paper during review: elephant in the lab series Read More »
Some of you might remember the stem cell clinic firm R3 Stem Cell. I have major concerns about some of what they are marketing including in the U.S. I was reminded of R3 Stem Cell again just now. The Associated Press (AP) ran a PR on R3 Stem like it was a news story. I
Media like the AP promote unproven stem cell clinics such as R3 Stem Cell Read More »
Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes
Where Kimera Labs fits into sphere of exosome companies Read More »
If you’ve never heard of the KRAS G12C mutation, it’s a particularly frightening mutation present in numerous cancers. Like the MYC oncogene, many people view mutations in RAS as undruggable, but new efforts show some glimmers of hope. The drug Sotorasib has been approved by the FDA to target the KRAS G12C mutation. Here’s a
Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs Read More »
Stem cell clinic firm US Stem Cell has just had a major paper retracted. Two of the notable authors on that paper are US Stem Cell leader Kristin Comella and stem cell researcher Thomas Ichim, who was senior author. It’s not clear to me if Comella currently has a role in the firm or not.
Stem cell clinic US Stem Cell has key paper retracted Read More »
What’s been going on in the stem cell and regenerative medicine field over the past week and what are some worthwhile things to read? Today’s post has recommended recent reads from the scientific literature and the media. I’ve also got our weekly stem cell/regenerative medicine quiz question and the answer to last week’s. You can
Recommended reads: FDA warning, COVID updates, stem cell pubs Read More »
Amongst all that is bouncing around within the stem cell clinic maelstrom out there, one thing stands out for me as the most troubling. I’m talking about for-profit experimentation on children, such as injection of kids with unproven stem cells for autism or cerebral palsy by unproven clinics. In my opinion it’s almost always going
Journal erred on Panama clinic stem cell for autism paper Read More »
The unproven stem cell clinic firm US Stem Cell Inc. is in a world of hurt. If a federal judge says you can no longer sell your key commercial offering, how do you survive as a company? US Stem probably has been thinking about that possibility for months. Still, it’s not yet clear where the
Can clinic biz US Stem reboot after losing suit? Its email to customers & more Read More »
What are your weekend reads? Many of us scientists read up on specific articles over the weekend that caught our eye during the last week or two. Here are some of my weekend reads plus some other stuff that just generally looked really interesting or unusual. The list includes both primary papers and news articles
Stem cell & other science weekend reads: arteries, diabetes, iffy metaphors, & more Read More »